Diabetes is a significant, well-established risk factor for multiple clinical outcomes including macrovascular events (stroke, myocardial infarction) and microvascular complications (neuropathy, nephropathy). 1 As treatment strategies for cardiovascular disease have been refined, the overall morbidity and mortality associated with cardiovascular events has declined. 2 Patients with diabetes who have acute cardiovascular events continue to have worse outcomes compared to patients without diabetes. 3, 4 This disparity is of particular importance given the high prevalence of diabetes. Epidemiological studies from the United States have shown that clinical outcomes in patients with diabetes have improved over time, but the increased prevalence of diabetes has resulted in an increase of the absolute rate of complications from diabetes. 5, 6 Similar increases in incidence have also been seen across the world. As a result, the international prevalence of diabetes is expected to continue to rise as risk factors for diabetes become more common. 7, 8 Despite the high prevalence and clear association of diabetes with adverse events, there are few contemporary data on the long-term outcomes from an international cohort of patients with diabetes. Prior studies have suggested that diabetes is associated with an increase in risk that is of similar magnitude as the presence of known atherothrombosis. 9 Uncertainty about the current long-term outcomes of stable patients with diabetes has led to significant debate over whether diabetes is truly a risk equivalent to coronary artery disease in this population. 10, 11 Furthermore, prior studies have suggested that diabetes may be associated with increased risk of heart failure; 12 however, it remains unclear whether this association is due to causal effects of diabetes or whether this association is due to other co-present medical conditions (e.g., hypertension, coronary artery disease, renal dysfunction). 13, 14 Thus, we sought to use the REACH registry to describe current long-term cardiovascular outcomes, including Similar increases in incidence have also been seen across the world. As a result, th th the e e in in inte te ern rn rnat at atio io ion na n l prevalence of diabetes is expected to continue to rise as risk factors for diabetes become more comm mm mon on on. . . 7, 8 Despit i e e e th th the e hi hi high gh gh p p pre re reva va vale le lenc nc ce e e an an nd clea a ar a asso oci i iatio o on n n of of of d d dia ab b bete te tes s wi wi with h adv dv dver er erse e e e e eve ve v nt nt nts, t t the he here re re ar r re e e fe fe few cont nt tem em e p po p r ra r ry y d d data on on on t t the h h l l lon on o g g g-te te term m m o o out u co om m mes s s fr fr from m m a a an n n in n nte e ern n natio i ional l l co o ohort rt t o o of pa p t t tients wi i with th th d d dia ia iabe be bete te tes s s. P P Pri ri rior or or s s stu t tudi di dies es es h h hav a ave e e su s sugg gg gges es este te ted d d th th that at at d d dia ia iab b bet et etes es es i i is s s as as asso so soci ci ciat at ated ed ed wit it ith h h an an an i i inc nc ncre re reas as ase e e in in in r r ris is isk k k th th tha a a a hospitalization for heart failure, and identify predictors of these cardiovascular events in an international cohort of patients with diabetes.
Methods

Study Design and Population
The REACH Registry is a prospective cohort of patients with either established atherosclerosis or significant risk factors for atherosclerosis that has been described previously in detail. [15] [16] [17] In order to be included in the registry, patients had to be 45 years old and have established atherosclerosis (coronary artery disease, peripheral artery disease or cerebrovascular disease) or 3 risk factors for atherosclerosis. Subjects were considered to have coronary artery disease if they had 1 or more of the following: prior myocardial infarction, history of coronary revascularization with PCI/CABG, stable angina, or prior history of unstable angina. Subjects were considered to have cerebrovascular disease if they had been diagnosed previously with either an ischemic stroke or transient ischemic attack by a neurologist or at the time of hospital discharge. Subjects with peripheral artery disease had either current intermittent claudication and an ankle-brachial index <0.9 or a history of intermittent claudication together with a prior intervention (angioplasty, stenting, atherectomy, peripheral arterial bypass grafting, amputation or other vascular intervention).
Risk factors for atherosclerosis included age ( 65 years for men, 70 years for women), hypertension (patients receiving treatment for hypertension and patients with blood pressure (systolic) 150 mmHg despite therapy), current therapy for hypercholesterolemia, ongoing tobacco use of 15 cigarettes/day, diabetes, diabetic nephropathy, ankle-brachial index <0.9, asymptomatic carotid stenosis 70%, and carotid intima media thickness 2 times that of adjacent sites. Diabetes was defined as those patients being treated for diabetes with either 3 risk factors for atherosclerosis. Subjects were considered to have coronary artery y y di d d se seas as se e if if hey had 1 or more of the following: prior myocardial infarction, history of coronary ry evascularization with PCI/CABG, stable angina, or prior history of unstable angina. Subjects w were re r conside er red d d to to hav ave e ce cere r br brov ov o as ascu cula lar r di dise seas a e i if t they y ha ha h d d be b en en d dia iagn gn nos osed p p pre re evi vi iou o sly y wi w th th ei i ith th her e an isch hem e i ic strok oke or tra ansient n isc schem mic c atta ac ck b by y y a a n neu urol logist o or at th th t e e time e o of ho hospita al discharg ge. Subje j cts with p perip pheral artery y disease had either current intermittent claudication and medications or lifestyle modifications at baseline or those patients with at least 2 fasting blood glucose measures >126 mg/dL who were not being treated with either medications or lifestyle modifications.
Patients were enrolled into the REACH Registry between 2003-2004 and were followed until 2008. Detailed personal and medical history was collected at baseline and then annually.
The initial follow-up was planned for up to 2 years but the registry was extended for an additional 2 years. While the majority of sites participated for the entire 4 years of follow-up, countries and sites that did not to participate in the 4-year follow-up were excluded from these analyses (n=45,227 subjects included and 23,009 excluded).
Institutional review boards in each country reviewed and approved the protocol according to the local requirements. Signed informed consent was required for all patients.
Endpoints
Patients in the REACH registry were followed for endpoints including cardiovascular death, myocardial infarction, stroke, hospitalization for ischemia, and hospitalization for heart failure.
The endpoints in the registry were investigator reported and were not adjudicated.
Cardiovascular death was defined as any death due to stroke, myocardial infarction or other cardiovascular etiology (e.g., deaths due to pulmonary embolism, any sudden death including unobserved and unexpected deaths unless proven to have a non-cardiovascular etiology by autopsy, following a vascular operation, procedure or amputation, death due to heart failure; death following a visceral or limb infarction; and any other death that could not be definitely attributed to a nonvascular cause or hemorrhage). Any myocardial infarction or stroke followed by a death in the next 28 days (regardless of the cause) was considered to be a fatal myocardial infarction or fatal stroke.
Institutional review boards in each country reviewed and approved the prot otoc ocol ol a a acc cc cor ordi d d ng o the local requirements. Signed informed consent was required for all patients. d
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Statistical Analysis
Categorical variables were calculated as frequencies and percentages and continuous variables were calculated as mean and standard deviations. Missing data at baseline were infrequent (under 1% or 2% for most variables). Imputations were performed using the multiple imputation approach for baseline characteristics which were missing. 18 The cohort of patients with diabetes were further classified by baseline characteristics into patients with risk factors only (no established atherothrombotic disease) or known atherothrombosis (patients with established coronary, peripheral, or cerebral artery disease). Patients with diabetes and known atherothrombosis were further stratified into those with known atherothrombosis and no prior ischemic event (established atherothrombosis but no prior myocardial infarction or stroke, e.g., patients with a history of revascularization), or atherothrombosis with prior ischemic events (myocardial infarction or stroke).
Four-year event rates in these patients were generated using the corrected group prognosis method which is an alternative approach to estimate four-year cumulative incidence patients with a history of revascularization), or atherothrombosis with prior ischemic events myo yo yoca ca card rd rdia ia ial l l in i i fa a arc rc rcti t on or stroke).
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The association between diabetes and hospitalization for heart failure was assessed via a logistic regression model due to limited data regarding the timing of this event. Variables included in the heart failure model were selected from the same candidate variables and using the same methods as used for the prior model.
Statistical significance was considered as a 2-sided probability of less than 0.05.
Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, North Carolina).
Results
A total of 45,224 of the patients who were enrolled in the REACH registry had follow-up at 4
years. Of those, 19,699 patients (43.6%) had diabetes. The mean age of patients in the subgroup with diabetes was 68.4 years and was similar to patients without diabetes (p=0.40). The overall proportion of patients from North America or Western Europe included in the analysis was 66.9%.
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Compared to those without diabetes, patients with diabetes were less frequently male or white, had lower rates of coronary artery disease (50.4 vs. 64.5%; p<0.001) and cerebrovascular disease (24.0% vs. 31.7%; p<0.001) at baseline. There were no differences between the groups in the proportion of patients with peripheral vascular disease at baseline (p=0.20). Prior history of heart failure was more common in patients with diabetes (16.1% vs. 11.8%; p<0.001).
Cardiovascular risk factors such as hypertension, hypercholesterolemia, obesity, and renal dysfunction were more common in patients with diabetes when compared to patients without ( Table 1 ).
The utilization of at least 1 antithrombotic drug at 4 years was lower in the patients with diabetes than in those without diabetes (83.7% vs. 91.0%, p<0.001). Aspirin was utilized in slightly over half the overall cohort with diabetes (53.3%) and without (57.9%). In the patients with diabetes, the use of aspirin was similar among those with known atherothrombosis and risk factors only (53.8% vs. 52.1%, p=0.08). Statin, ACEi/ARB, and diuretics were used more commonly in patients with diabetes while beta-blockers were used more frequently in patients without diabetes (48.5% vs. 53.5%; p<0.001).
In the patients with diabetes, the most commonly prescribed treatments were biguanides (42.3%) followed by sulfonylureas (40.2%), insulin (31.2%) and thiazolidinediones (16.2%). In patients with diabetes, patients with known atherothrombosis were less frequently treated with anti-hyperglycemic drugs (84.8% vs. 91.7%, p<0.001, Supplemental Table 1 ).
The overall hazard rate of cardiovascular death, myocardial infarction, or stroke (adjusted for age and sex) was greater in patients with diabetes as compared to patients without diabetes (16.5% vs. 13.1%, p<0.001, Table 2 (4.4% vs. 3.2%, p<0.001) but there was no difference in non-fatal stroke (5.7% vs. 5.3%, p=0.14). There was also a marked increase in all-cause mortality in patients with diabetes compared to those without (14.3% vs. 9.9%, p<0.001). Similar results were seen in the cohort of patients on hypoglycemic agents at baseline (Supplemental Table 2 ).
After adjusting for potential confounders, the presence of diabetes was associated with increased risk of the primary composite endpoint of cardiovascular death, MI, or stroke; allcause mortality; cardiovascular death; non-cardiovascular death; non-fatal MI; non-fatal stroke;
and the composite endpoint of cardiovascular death, MI, stroke, or CV hospitalization (Supplemental Table 3 ).
Among patients with diabetes, those with known atherothrombosis had significantly higher rates of cardiovascular death, myocardial infarction, or stroke (19.5% vs. 9.5%, p<0.001, Figure 1 ). All cause mortality and non-cardiovascular death were also higher in patients with known atherothrombosis when compared to patients with risk factors only. In patients with diabetes and prior coronary revascularization but no prior MI, the hazard rate of cardiovascular death, non-fatal myocardial infarction, or stroke was 14.8% (13.31-16.21) . At 4 years, the hazard rate for cardiovascular death was 7.7% (6.6-8.81) while the hazard rate for noncardiovascular death was 5.8% (4.82-6.81). The hazard rate for non-fatal myocardial infarction was 4.1% (3.24-4.89) while the hazard rate for non-fatal stroke was 4.6% (3.73-5.48).
When compared to those patients in REACH without diabetes, the presence of diabetes was associated with a 33% increase in the odds of hospitalization for heart failure that was present even after adjusting for potential confounders (9.4% vs. 5.9%, OR adj 1.33, 95% CI 1.18-1.50, Figure 2 ). The association between diabetes and hospitalization for heart failure was seen in the patients with known atherothrombosis (OR adj 1.30, 95% CI 1.14-1.48) and risk factors Among patients with diabetes, those with known atherothrombosis had sig g gni ni nifi fi fica ca cant nt ntly ly ly higher rates of cardiovascular death, myocardial infarction, or stroke (19.5% vs. 9.5%, p<0.001, r
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Given that patients with diabetes were found to be at increased risk of cardiovascular events, we sought to identify the predictors of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke specifically in the population with diabetes. When restricting the populations to include only patients with diabetes, a multivariate analysis found the greatest predictors for cardiovascular death, non-fatal MI, and non-fatal stroke were the presence of polyvascular disease and congestive heart failure at baseline ( Similarly, patients with diabetes were at increased risk of hospitalization for heart failure.
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Thus, we sought to identify the predictors of hospitalization for heart failure in the population with diabetes. In patients with diabetes, the presence of baseline congestive heart failure had the largest association with hospitalization for heart failure ( Table 4) . Geographic region was also a significant predictor of hospitalization for hospitalization for heart failure. As compared to North America, the risk of hospitalization for heart failure was higher in Eastern Europe (OR 1.38, 95% CI Table 5 ).
Discussion
Our data show that 1 out of 6 patients in an international cohort with diabetes and either established atherothrombosis or additional risk factors for atherothrombosis experienced a cardiovascular death, myocardial infarction, or stroke during 4 years of follow-up. Rates of cardiovascular events, including CV mortality, were significantly higher in patients with diabetes when compared to patients without diabetes. While there has been significant progress made in the management and treatment of patients with cardiovascular disease, [20] [21] [22] these data provide evidence that rates of cardiovascular events remain elevated in patients with diabetes. Thus, the presence of diabetes continues to be a significant risk factor for ischemic events despite the utilization of evidence-based therapies in a contemporary, international cohort of patients.
In addition to being at increased risk of ischemic events, we also found an independent association between diabetes and the risk of hospitalization for heart failure. The predictors associated with hospitalization for heart failure were similar to the factors associated with future ischemic events; however, a prior history of heart failure was the strongest predictor of future heart failure hospitalizations. The risk of hospitalization for heart failure also varied by region.
These findings are consistent with prior studies that have found geographic differences in both Our data show that 1 out of 6 patients in an international cohort with diabetes and e e eit it ithe he h r r r established atherothrombosis or additional risk factors for atherothrombosis experi i ien en enced d d a r cardiovascular dea eath, myocardial infarction, or stro oke during 4 years of f follow-up. Rates of ca ca ard d diovascul l la a ar e e eve ve vents, s, s, i i inc nc nclu lu luding ng ng C C CV V V mo mo mort r al al alit it ity, y y we ere e e sign gn gnif if ific ic ican antl tl tly y y hi hi high gh gher er er in pa pa ati ti tien en ents ts ts wit it th h h di di diab ab abet e e es wh wh whe en en compare re r d to to pat t tie ents wi wi with t t out di d d a a abetes. W W Whil le the e ere re re h h ha a as bee e en n n signif fi ican an ant pr p og gre re ress m ma a ade in n f f f f he manage g g ment and treatment of pa p p tients with cardiovascular disease, , , 20-22 22 these data pr p p ovide the incidence of heart failure as well as differences in the effectiveness of therapies for heart failure. For example, the TOPCAT trial that evaluated the effectiveness of spironolactone in patients with heart failure and preserved ejection fraction found an approximately 3-fold difference in the rate of hospitalization for heart failure in patients in the United States, Canada, Brazil, or Argentina as compared to those treated in either Russia or Georgia. 23 Our data support prior studies which have also found an association between diabetes and increased risk of hospitalization for heart failure. 24 Despite these data, the association between diabetes and heart failure remains under-recognized by clinicians. 25 Nonetheless, in an era in which there is increasing emphasis on chronic disease management as a strategy to contain healthcare costs, these findings highlight the significance of diabetes and the need for therapies that improve outcomes in patients with diabetes.
Multiple hypotheses have been proposed for the mechanism behind the association of diabetes and heart failure including an increased burden of ischemic heart disease, other medical co-morbidities associated with diabetes, medications used in the treatment of diabetes, or a direct metabolic effect of altered glucose regulation, but the exact mechanism remains poorly defined. 26 In the REACH registry, we found a 33% increase in the risk of hospitalization for heart failure in patients with diabetes. Similar associations were seen in patients with diabetes and prior ischemic events (MI, stroke), diabetes and known atherothrombosis but no prior ischemic events, and diabetes with risk factors only for atherothrombosis. While these findings can only be viewed as hypothesis-generating, they suggest that the mechanism of the association between diabetes and heart failure could be related to a process specific to patients with diabetes rather than an increased burden of atherothrombosis. 27, 28 We did, however, find that the risk of future ischemic events in patients with diabetes healthcare costs, these findings highlight the significance of diabetes and the need d d fo fo for r r th th her er erap ap apie ie ies hat improve outcomes in patients with diabetes.
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was associated with the extent and severity of atherothrombosis (number of vascular beds affected by atherothrombosis, the presence of recent ischemic events) as well as other risk factors for cardiovascular events such as increasing age, prior history of heart failure, and renal dysfunction. These risk factors have been shown previously to affect outcomes in a general population of patients at high risk for ischemic events. 17 Our findings extend these observations and show that the extent of vascular disease remains a powerful predictor of ischemic events specifically in patients with diabetes.
As shown from these data, the presence of diabetes increases significantly the risk of ischemic events. Yet, prior studies have not found the use of anti-hyperglycemic therapies to clearly reduce the risk of macrovascular events (e.g., myocardial infarction) in patients with
Type II diabetes despite improving glycemic control. [28] [29] [30] [31] [32] While the lack of cardiovascular benefit from glycemic control does not negate the importance of glycemic control, it does suggest that attempts to improve cardiovascular outcomes in patients with diabetes should be broad and focus on pathways other than those that only affect glycemic control. For example, prior studies of anti-platelet therapies in stable patients with established atherothrombosis have found that enhanced platelet inhibition with clopidogrel 75 mg daily and aspirin 81 mg daily reduced the incidence of cardiovascular death, myocardial infarction, or stroke when compared to patients treated with aspirin only. 33 Ongoing trials of dual antiplatelet therapy in patients with diabetes and established atherosclerosis but no prior ischemic events will test the hypothesis that enhanced antiplatelet therapy can reduce cardiovascular events in patients with diabetes and atherosclerosis (clinicaltrials.gov Indentifier: NCT01991795).
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Our findings should be considered in light of some limitations. This analysis was not a population based observational study, and the prevalence of some risk factors was influenced by clearly reduce the risk of macrovascular events (e.g., myocardial infarction) in pa a ati ti tien en ents ts ts w w wit it ith h h Type II diabetes despite improving glycemic control. [28] [29] [30] [31] [32] While the lack of cardiovascular f bene e efi fi fit t t fr fr from om om g glyce ce cemi m c control does not negate the he he i i im m mportance of glycemi mi mic control, it does u u ug gg ggest that att t tem em emp pts s s to to t i i imp mp mpro ro rov ve ve c c car ar ardi di diov ov o ascu cu cula ar ou ut t tcom m me e es i i in n n pa pati ti tient nt nts s w w with h dia ia iabe be bete te tes s s sh s s ou ou ould d d b b be e e br r roa oa oad d d and fo fo oc cu c s on n n pa a ath hw h ay ys s s ot ot other r r th t t a a an t tho o ose se se that t o o onl ly y y a a affe fe ect t t g g gly y yc ce cemi m m c c c c cont nt tro ro rol. l Fo o or e exa am m mple, , , t pr pr prio io ior r r st st stud d udie ie ies s s of of of a a ant nt nti i i-pl pl plat at atel el elet et et t t the he her r rap ap apie ie ies s s in in in s s sta ta tabl bl ble e e pa pa pati ti tien en ents ts ts wit it ith h h es es esta ta tabl bl blis is ishe he hed d d at at athe he hero ro roth th thro ro romb mb mbos os osis is is h h hav a ave e e the inclusion criteria for the registry. This registry captured significant clinical data, including medication use, that were utilized in the adjusted analyses, but the duration of diabetes and the degree of glycemic control in patients with diabetes as measured by HbA1c or fasting plasma glucose were not available. The endpoints in this observational registry were reported by investigators and were not adjudicated by an independent clinical events committee as is common in many randomized clinical trials. Although the relationship between diabetes and heart failure was present even after controlling for geography, it is possible that the geographic variation seen in the association with hospitalization for heart failure reflects differences in the frequency for which hospital based treatment strategies were utilized in these particular areas.
Finally, 4-year follow-up was not obtained from all patients. This was related to whether the research site that initially enrolled the patient participated in the follow-up and not due to patient specific factors, thus would not be expected to bias the results.
These data show that the presence of diabetes significantly increases the risk of cardiovascular events. This risk is present both in patients with diabetes and established atherosclerosis and those with diabetes who have only risk factors for atherosclerosis. In patients with diabetes, the presence of heart failure in particular is also a significant risk marker associated with increased risk of cardiovascular events. While current therapies have improved overall outcomes for patients with cardiovascular disease, the high incidence of events in patients with diabetes and risk factors for cardiovascular disease highlights the need for further therapies that can improve outcomes in this particularly high risk patient population.
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